| | Business Summary | | POZEN
Inc.
is
a
commercially
focused
pharmaceutical
development
company
committed
to
building
a
portfolio
of
products
in
targeted
therapeutic
areas,
through
a
combination
of
innovation
and
in
licensing.
The
Company's
initial
therapeutic
focus
is
on
the
migraine
market.
The
Company
has
completed
all
five
of
its
planned
Phase
3
clinical
trials
for
its
lead
product
candidate,
MT
100,
which
is
being
developed
as
an
oral
first-line
therapy
for
the
treatment
of
migraine.
During
the
second
half
of
20001,
the
Company
intends
to
initiate
a
Phase
3
trial
for
MT
300,
which
the
Company
is
developing
as
an
injectable
treatment
for
severe
migraine
attacks.
POZEN's
migraine
portfolio
also
contains
a
migraine
prophylactic
agent,
MT
500,
set
to
enter
a
Phase
2
clinical
trial
in
the
second
half
of
2001,
and
one
additional
product
candidate
for
the
treatment
of
acute
migraine,
MT
400,
for
which
the
Company
has
completed
a
Phase
2
clinical
trial. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | POZN
is
a
pharmaceutical
company
engaged
in
the
development
of
products
in
targeted
therapeutic
areas.
The
Company's
initial
area
of
focus
is
migraine.
For
the
six
months
ended
6/30/01,
the
Company
reported
no
revenues.
Net
loss
applicable
to
Common
decreased
66%
to
$8.9
million.
Results
reflect
increased
interest
income
due
to
higher
levels
of
cash
and
cash
equivalents
and
the
absence
of
a
$16.9
million
preferred
stock
dividend. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| John Plachetka, Ph.D., 47
Chairman,
Pres, CEO | $351K | Peter Wise, M.D., 66
Vice
Chairman | -- | Matthew Czajkowski, 51
CFO,
Sr. VP, Fin. and Admin. | 187K | Andrew Finn, 51
Exec.
VP, Product Devel. | 272K | Kristina Adomonis, 46
Sr.
VP , Bus. Devel. | 205K | | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/p/pozn.gif)